| Nov 13 |
Kezar struck again with second FDA hold
|
| Nov 13 |
Kezar Life Sciences GAAP EPS of -$2.78 beats by $0.37
|
| Nov 12 |
Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update
|
| Oct 29 |
Looking Into Kezar Life Sciences's Recent Short Interest
|
| Oct 28 |
Kezar Life Sciences announces 1-for-10 reverse stock split
|
| Oct 28 |
Kezar Life Sciences Announces 1-for-10 Reverse Stock Split
|
| Oct 18 |
Kezar Life Sciences discontinues lupus nephritis programme after fatalities
|
| Oct 17 |
Penny Stock Kezar Life Sciences Rejects Acquisition Deal From Concentra Biosciences At $1.10/Share, Shelves Mid-Stage Lupus Nephritis Study
|
| Oct 17 |
Kezar stock falls 11% after board rejects Concentra offer (update)
|
| Oct 17 |
Kezar discontinues development of zetomipzomib for lupus nephritis
|
